Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2011 (2011), Article ID 932351, 12 pages
http://dx.doi.org/10.4061/2011/932351
Review Article

Heterogeneity in Multiple Sclerosis: Scratching the Surface of a Complex Disease

1Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Headington, Oxford, OX3 7BN, UK
2Department of Clinical Neurology, University of Oxford, The West Wing, John Radcliffe Hospital, Oxford, OX3 9DU, UK
3Nuffield Department of Clinical Medicine, University of Oxford, Henry Wellcome Building for Molecular Physiology, Old Road Campus, Headington, Oxford OX3 7BN, UK

Received 8 September 2010; Accepted 27 October 2010

Academic Editor: Sreeram Ramagopalan

Copyright © 2011 Giulio Disanto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker, “Multiple sclerosis,” The New England Journal of Medicine, vol. 343, no. 13, pp. 938–952, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. S. V. Ramagopalan, R. Dobson, U. C. Meier, and G. Giovannoni, “Multiple sclerosis: risk factors, prodromes, and potential causal pathways,” The Lancet Neurology, vol. 9, no. 7, pp. 727–739, 2010. View at Publisher · View at Google Scholar
  3. M. S. Freedman, E. J. Thompson, F. Deisenhammer et al., “Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement,” Archives of Neurology, vol. 62, no. 6, pp. 865–870, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. K. Rejdak, S. Jackson, and G. Giovannoni, “Multiple sclerosis: a practical overview for clinicians,” British Medical Bulletin, vol. 95, no. 1, pp. 79–104, 2010. View at Publisher · View at Google Scholar · View at PubMed
  5. A. Scalfari, A. Neuhaus, A. Degenhardt et al., “The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability,” Brain, vol. 133, no. 7, pp. 1914–1929, 2010. View at Publisher · View at Google Scholar · View at PubMed
  6. A. Compston and A. Coles, “Multiple sclerosis,” The Lancet, vol. 359, no. 9313, pp. 1221–1231, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. C. Lucchinetti, W. Brück, J. Parisi, B. Scheithauer, M. Rodriguez, and H. Lassmann, “Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination,” Annals of Neurology, vol. 47, no. 6, pp. 707–717, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Koch, E. Kingwell, P. Rieckmann, and H. Tremlett, “The natural history of primary progressive multiple sclerosis,” Neurology, vol. 73, no. 23, pp. 1996–2002, 2009. View at Publisher · View at Google Scholar · View at PubMed
  9. C. Confavreux and S. Vukusic, “Natural history of multiple sclerosis: a unifying concept,” Brain, vol. 129, no. 3, pp. 606–616, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. D. A. Cottrell, M. Kremenchutzky, G. P. A. Rice, W. Hader, J. Baskerville, and G. C. Ebers, “The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis,” Brain, vol. 122, no. 4, pp. 641–647, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Confavreux, S. Vukusic, T. Moreau, and P. Adeleine, “Relapses and progression of disability in multiple sclerosis,” The New England Journal of Medicine, vol. 343, no. 20, pp. 1430–1438, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. S. J. Pittock, R. L. McClelland, W. T. Mayr et al., “Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study,” Annals of Neurology, vol. 56, no. 2, pp. 303–306, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J.-I. Kira, “Neuromyelitis optica and Asian phenotype of multiple sclerosis,” Annals of the New York Academy of Sciences, vol. 1142, pp. 58–71, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. V. A. Lennon, T. J. Kryzer, S. J. Pittock, A. S. Verkman, and S. R. Hinson, “IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel,” Journal of Experimental Medicine, vol. 202, no. 4, pp. 473–477, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. J. H. Simon and B. K. Kleinschmidt-DeMasters, “Variants of multiple sclerosis,” Neuroimaging Clinics of North America, vol. 18, no. 4, pp. 703–716, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. W. Hu and C. F. Lucchinetti, “The pathological spectrum of CNS inflammatory demyelinating diseases,” Seminars in Immunopathology, vol. 31, no. 4, pp. 439–453, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. C. Jersild, T. Fog, G. S. Hansen, M. Thomsen, A. Svejgaard, and B. Dupont, “Histocompatibility determinants in multiple sclerosis, with special reference to clinical course,” The Lancet, vol. 2, no. 7840, pp. 1221–1225, 1973. View at Google Scholar
  18. A. Fogdell, J. Hillert, C. Sachs, and O. Olerup, “The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5*0101 allele,” Tissue Antigens, vol. 46, no. 4, pp. 333–336, 1995. View at Google Scholar · View at Scopus
  19. S. J. Caillier, F. Briggs, B. A. C. Cree et al., “Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis,” Journal of Immunology, vol. 181, no. 8, pp. 5473–5480, 2008. View at Google Scholar · View at Scopus
  20. S. V. Ramagopa and G. C. Ebers, “Multiple sclerosis: major histocompatibility complexity and antigen presentation,” Genome Medicine, vol. 1, no. 11, p. 105, 2009. View at Publisher · View at Google Scholar · View at PubMed
  21. J. R. Oksenberg, L. F. Barcellos, B. A. C. Cree et al., “Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans,” American Journal of Human Genetics, vol. 74, no. 1, pp. 160–167, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. C. Ballerini, F. R. Guerini, G. Rombolà et al., “HLA-multiple sclerosis association in Continental Italy and correlation with disease prevalence in Europe,” Journal of Neuroimmunology, vol. 150, no. 1-2, pp. 178–185, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. O. J. Kwon, A. Karni, S. Israel et al., “HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews,” Archives of Neurology, vol. 56, no. 5, pp. 555–560, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Masterman, A. Ligers, T. Olsson, M. Andersson, O. Olerup, and J. Hillert, “HLA-DR15 is associated with lower age at onset in multiple sclerosis,” Annals of Neurology, vol. 48, no. 2, pp. 211–219, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. L. F. Barcellos, S. Sawcer, P. P. Ramsay et al., “Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis,” Human Molecular Genetics, vol. 15, no. 18, pp. 2813–2824, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. S. V. Ramagopalan, A. P. Morris, D. A. Dyment et al., “The inheritance of resistance alleles in multiple sclerosis,” PLoS Genetics, vol. 3, no. 9, pp. 1607–1613, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. D. A. Dyment, B. M. Herrera, M. Z. Cader et al., “Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance,” Human Molecular Genetics, vol. 14, no. 14, pp. 2019–2026, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. T. Matsuoka, T. Matsushita, M. Osoegawa et al., “Association of the HLA-DRB1 alleles with characteristic MRI features of Asian multiple sclerosis,” Multiple Sclerosis, vol. 14, no. 9, pp. 1181–1190, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. M. G. Marrosu, R. Murru, M. R. Murru et al., “Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia,” Human Molecular Genetics, vol. 10, no. 25, pp. 2907–2916, 2001. View at Google Scholar · View at Scopus
  30. M. A. Pina, J. R. Ara, P. Lasierra, P. J. Modrego, and L. Larrad, “Study of HLA as a predisposing factor and its possible influence on the outcome of multiple sclerosis in the sanitary district of Calatayud, northern Spain,” Neuroepidemiology, vol. 18, no. 4, pp. 203–209, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Bergamaschi, M. A. Leone, M. E. Fasano et al., “HLA-class I markers and multiple sclerosis susceptibility in the Italian population,” Genes and Immunity, vol. 11, no. 2, pp. 173–180, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. T. W. Yeo, P. L. De Jager, S. G. Gregory et al., “A second major histocompatibility complex susceptibility locus for multiple sclerosis,” Annals of Neurology, vol. 61, no. 3, pp. 228–236, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. B. Brynedal, K. Duvefelt, G. Jonasdottir et al., “HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis,” PLoS ONE, vol. 2, no. 7, Article ID e664, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. J. D. Rioux, P. Goyette, T. J. Vyse et al., “Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 44, pp. 18680–18685, 2009. View at Publisher · View at Google Scholar · View at PubMed
  35. M. R. Lincoln, S. V. Ramagopalan, M. J. Chao et al., “Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 18, pp. 7542–7547, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. M. J. Chao, S. V. Ramagopalan, B. M. Herrera et al., “Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex,” Human Molecular Genetics, vol. 18, no. 2, pp. 261–266, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. M. J. D'Netto, H. Ward, K. M. Morrison et al., “Risk alleles for multiple sclerosis in multiplex families,” Neurology, vol. 72, no. 23, pp. 1984–1988, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. D. A. Hafler, A. Compston, S. Sawcer et al., “Risk alleles for multiple sclerosis identified by a genomewide study,” The New England Journal of Medicine, vol. 357, no. 9, pp. 851–862, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. F. Lundmark, K. Duvefelt, E. Iacobaeus et al., “Variation in interleukin 7 receptor α chain (IL7R) influences risk of multiple sclerosis,” Nature Genetics, vol. 39, no. 9, pp. 1108–1113, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. F. Weber, B. Fontaine, I. Cournu-Rebeix et al., “IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations,” Genes and Immunity, vol. 9, no. 3, pp. 259–263, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. S. G. Gregory, S. Schmidt, P. Seth et al., “Interleukin 7 receptor α chain (IL7R) shows allelic and functional association with multiple sclerosis,” Nature Genetics, vol. 39, no. 9, pp. 1083–1091, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. “Refining genetic associations in multiple sclerosis,” The Lancet Neurology, vol. 7, no. 7, pp. 567–569, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. P. L. De Jager, C. Baecher-Allan, L. M. Maier et al., “The role of the CD58 locus in multiple sclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 13, pp. 5264–5269, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. M. Ban, A. Goris, Å. R. Lorentzen et al., “Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor,” European Journal of Human Genetics, vol. 17, no. 10, pp. 1309–1313, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. M. Bahlo, D. R. Booth, S. A. B. et al., “Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20,” Nature Genetics, vol. 41, no. 7, pp. 824–828, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. P. R. Burton, D. G. Clayton, L. R. Cardon et al., “Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants,” Nature Genetics, vol. 39, no. 11, pp. 1329–1337, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. Y. S. Aulchenko, I. A. Hoppenbrouwers, S. V. Ramagopalan et al., “Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis,” Nature Genetics, vol. 40, no. 12, pp. 1402–1403, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. M. Zoledziewska, G. Costa, M. Pitzalis et al., “Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia,” Genes and Immunity, vol. 10, no. 1, pp. 15–17, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. I. A. Hoppenbrouwers, Y. S. Aulchenko, A. C. Janssens et al., “Replication of CD58 and CLEC16A as genome-wide significant risk genes for multiple sclerosis,” Journal of Human Genetics, vol. 54, no. 11, pp. 676–680, 2009. View at Publisher · View at Google Scholar · View at PubMed
  50. S. Wieczorek, S. Hoffjan, A. Chan et al., “Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients,” Genes and Immunity, vol. 10, no. 6, pp. 591–595, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. I. A. Hoppenbrouwers, Y. S. Aulchenko, G. C. Ebers et al., “EVI5 is a risk gene for multiple sclerosis,” Genes and Immunity, vol. 9, no. 4, pp. 334–337, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. J. L. McCauley and J. P. Hussman, “Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci,” Human Molecular Genetics, vol. 19, no. 5, pp. 953–962, 2009. View at Publisher · View at Google Scholar · View at PubMed
  53. D. R. Booth, R. N. Heard, G. J. Stewart et al., “The expanding genetic overlap between multiple sclerosis and type I diabetes,” Genes and Immunity, vol. 10, no. 1, pp. 11–14, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. P. L. De Jager, X. Jia, J. Wang et al., “Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci,” Nature Genetics, vol. 41, no. 7, pp. 776–782, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. C. E. Egwuagu, “STAT3 in CD4+ T helper cell differentiation and inflammatory diseases,” Cytokine, vol. 47, no. 3, pp. 149–156, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. S. Sanna, M. Pitzalis, M. Zoledziewska et al., “Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis,” Nature Genetics, vol. 42, no. 6, pp. 495–497, 2010. View at Publisher · View at Google Scholar · View at PubMed
  57. G. C. DeLuca, S. V. Ramagopalan, B. M. Herrera et al., “An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 52, pp. 20896–20901, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. J. Stankovich, H. Butzkueven, M. Marriott et al., “HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis,” Tissue Antigens, vol. 74, no. 1, pp. 17–21, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. L. Romero-Pinel, J. M. Pujal, S. Martinez-Yelamos et al., “HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population,” European Journal of Neurology. In Press. View at Publisher · View at Google Scholar · View at PubMed
  60. I. Cournu-Rebeix, E. Génin, E. Leray et al., “HLA-DRB1* 15 allele influences the later course of relapsing remitting multiple sclerosis,” Genes and Immunity, vol. 9, no. 6, pp. 570–574, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. M. Podbielska and E. L. Hogan, “Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis?” Multiple Sclerosis, vol. 15, no. 9, pp. 1011–1029, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. S. E. Baranzini, J. Wang, R. A. Gibson et al., “Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis,” Human Molecular Genetics, vol. 18, no. 4, pp. 767–778, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. M. H. Barnett, J. D. Parratt, J. D. Pollard, and J. W. Prineas, “MS: is it one disease?” International MS Journal, vol. 16, no. 2, pp. 57–65, 2009. View at Google Scholar · View at Scopus
  64. H. Lassmann, W. Brück, and C. F. Lucchinetti, “The immunopathology of multiple sclerosis: an overview,” Brain Pathology, vol. 17, no. 2, pp. 210–218, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. F. W. Gay, T. J. Drye, G. W. A. Dick, and M. M. Esiri, “The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis: identification and characterization of the primary demyelinating lesion,” Brain, vol. 120, no. 8, pp. 1461–1483, 1997. View at Publisher · View at Google Scholar · View at Scopus
  66. J. S. Tzartos, M. A. Friese, M. J. Craner et al., “Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis,” American Journal of Pathology, vol. 172, no. 1, pp. 146–155, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. M. Calabrese, M. Filippi, and P. Gallo, “Cortical lesions in multiple sclerosis,” Nature Reviews Neurology, vol. 6, no. 8, pp. 438–444, 2010. View at Publisher · View at Google Scholar · View at PubMed
  68. D. T. Chard, C. M. Griffin, M. A. McLean et al., “Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis,” Brain, vol. 125, no. 10, pp. 2342–2352, 2002. View at Google Scholar · View at Scopus
  69. N. De Stefano, P. M. Matthews, M. Filippi et al., “Evidence of early cortical atrophy in MS: relevance to white matter changes and disability,” Neurology, vol. 60, no. 7, pp. 1157–1162, 2003. View at Google Scholar · View at Scopus
  70. C. M. Dalton, D. T. Chard, G. R. Davies et al., “Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes,” Brain, vol. 127, no. 5, pp. 1101–1107, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. A. Kutzelnigg, C. F. Lucchinetti, C. Stadelmann et al., “Cortical demyelination and diffuse white matter injury in multiple sclerosis,” Brain, vol. 128, no. 11, pp. 2705–2712, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. K. Ozawa, G. Suchanek, H. Breitschopf et al., “Patterns of oligodendroglia pathology in multiple sclerosis,” Brain, vol. 117, no. 6, pp. 1311–1322, 1994. View at Google Scholar · View at Scopus
  73. J. W. Prineas, E. E. Kwon, E.-S. Cho et al., “Immunopathology of secondary-progressive multiple sclerosis,” Annals of Neurology, vol. 50, no. 5, pp. 646–657, 2001. View at Publisher · View at Google Scholar · View at Scopus
  74. R. Magliozzi, O. Howell, A. Vora et al., “Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology,” Brain, vol. 130, no. 4, pp. 1089–1104, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. A. Dal Bianco, M. Bradl, J. Frischer, A. Kutzelnigg, K. Jellinger, and H. Lassmann, “Multiple sclerosis and Alzheimer's disease,” Annals of Neurology, vol. 63, no. 2, pp. 174–183, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. D. Franciotta, M. Salvetti, F. Lolli, B. Serafini, and F. Aloisi, “B cells and multiple sclerosis,” The Lancet Neurology, vol. 7, no. 9, pp. 852–858, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. B. Serafini, B. Rosicarelli, D. Franciotta et al., “Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain,” Journal of Experimental Medicine, vol. 204, no. 12, pp. 2899–2912, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. N. Evangelou, G. C. DeLuca, T. Owens, and M. M. Esiri, “Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions,” Brain, vol. 128, no. 1, pp. 29–34, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. M. M. Esiri, “MS: is it one disease?” International MS Journal, vol. 16, no. 2, pp. 39–41, 2009. View at Google Scholar
  80. E. C. W. Breij, B. P. Brink, R. Veerhuis et al., “Homogeneity of active demyelinating lesions in established multiple sclerosis,” Annals of Neurology, vol. 63, no. 1, pp. 16–25, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. M. H. Barnett and J. W. Prineas, “Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion,” Annals of Neurology, vol. 55, no. 4, pp. 458–468, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. M. H. Barnett, J. D. E. Parratt, E.-S. Cho, and J. W. Prineas, “Immunoglobulins and complement in postmortem multiple sclerosis tissue,” Annals of Neurology, vol. 65, no. 1, pp. 32–46, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. L. Bø, C. A. Vedeler, H. I. Nyland, B. D. Trapp, and S. J. Mørk, “Subpial demyelination in the cerebral cortex of multiple sclerosis patients,” Journal of Neuropathology and Experimental Neurology, vol. 62, no. 7, pp. 723–732, 2003. View at Google Scholar · View at Scopus
  84. G. C. DeLuca, G. C. Ebers, and M. M. Esiri, “Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts,” Brain, vol. 127, no. 5, pp. 1009–1018, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. G. C. DeLuca, K. Williams, N. Evangelou, G. C. Ebers, and M. M. Esiri, “The contribution of demyelination to axonal loss in multiple sclerosis,” Brain, vol. 129, no. 6, pp. 1507–1516, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. S. S. Zamvil and L. Steinman, “The T lymphocyte in experimental allergic encephalomyelitis,” Annual Review of Immunology, vol. 8, pp. 579–621, 1990. View at Google Scholar · View at Scopus
  87. H. P. M. Brok, M. Van Meurs, E. Blezer et al., “Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody,” Journal of Immunology, vol. 169, no. 11, pp. 6554–6563, 2002. View at Google Scholar · View at Scopus
  88. B. M. Segal, C. S. Constantinescu, A. Raychaudhuri, L. Kim, R. Fidelus-Gort, and L. H. Kasper, “Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study,” The Lancet Neurology, vol. 7, no. 9, pp. 796–804, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. J. Brettschneider, A. Czerwoniak, M. Senel et al., “The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS),” PLoS ONE, vol. 5, no. 8, pp. 1–6, 2010. View at Publisher · View at Google Scholar · View at PubMed
  90. F. Sellebjerg, L. Börnsen, M. Khademi et al., “Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS,” Neurology, vol. 73, no. 23, pp. 2003–2010, 2009. View at Publisher · View at Google Scholar · View at PubMed
  91. A. Bar-Or, L. Fawaz, B. Fan et al., “Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?” Annals of Neurology, vol. 67, no. 4, pp. 452–461, 2010. View at Publisher · View at Google Scholar · View at PubMed
  92. A. Bar-Or, P. A. J. Calabresi, D. Arnold et al., “Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase 1 trial,” Annals of Neurology, vol. 63, no. 6, pp. 395–400, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. S. L. Hauser, E. Waubant, D. L. Arnold et al., “B-cell depletion with rituximab in relapsing-remitting multiple sclerosis,” The New England Journal of Medicine, vol. 358, no. 7, pp. 676–688, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  94. M. A. Friese and L. Fugger, “Pathogenic CD8+ T cells in multiple sclerosis,” Annals of Neurology, vol. 66, no. 2, pp. 132–141, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. A. Junker, J. Ivanidze, J. Malotka et al., “Multiple sclerosis: T-cell receptor expression in distinct brain regions,” Brain, vol. 130, no. 11, pp. 2789–2799, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. C. Skulina, S. Schmidt, K. Dornmair et al., “Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 8, pp. 2428–2433, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Jacobsen, S. Cepok, E. Quak et al., “Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients,” Brain, vol. 125, no. 3, pp. 538–550, 2002. View at Google Scholar · View at Scopus
  98. T. Korn, E. Bettelli, M. Oukka, and V. K. Kuchroo, “IL-17 and Th17 cells,” Annual Review of Immunology, vol. 27, pp. 485–517, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. C. Dong, “TH17 cells in development: an updated view of their molecular identity and genetic programming,” Nature Reviews Immunology, vol. 8, no. 5, pp. 337–348, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  100. M. E. Fransson, L. S. E. Liljenfeldt, J. Fagius, T. H. Tötterman, and A. S. I. Loskog, “The T-cell pool is anergized in patients with multiple sclerosis in remission,” Immunology, vol. 126, no. 1, pp. 92–101, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  101. V. Brucklacher-Waldert, K. Stuerner, M. Kolster, J. Wolthausen, and E. Tolosa, “Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis,” Brain, vol. 132, no. 12, pp. 3329–3341, 2009. View at Publisher · View at Google Scholar · View at PubMed
  102. G. Frisullo, F. Angelucci, M. Caggiula et al., “pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity,” Journal of Neuroscience Research, vol. 84, no. 5, pp. 1027–1036, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. C. Du, C. Liu, J. Kang et al., “MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis,” Nature Immunology, vol. 10, no. 12, pp. 1252–1259, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  104. V. Viglietta, C. Baecher-Allan, H. L. Weiner, and D. A. Hafler, “Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis,” Journal of Experimental Medicine, vol. 199, no. 7, pp. 971–979, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. J. Haas, A. Hug, A. Viehöver et al., “Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis,” European Journal of Immunology, vol. 35, no. 11, pp. 3343–3352, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  106. M. Kumar, N. Putzki, V. Limmroth et al., “CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis,” Journal of Neuroimmunology, vol. 180, no. 1-2, pp. 178–184, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  107. J. Smolders, P. Menheere, M. Thewissen et al., “Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis,” Journal of Steroid Biochemistry and Molecular Biology, vol. 121, no. 1-2, pp. 243–246, 2010. View at Publisher · View at Google Scholar · View at PubMed
  108. A. Ascherio, K. L. Munger, and K. C. Simon, “Vitamin D and multiple sclerosis,” The Lancet Neurology, vol. 9, no. 6, pp. 599–612, 2010. View at Publisher · View at Google Scholar
  109. K. Venken, N. Hellings, T. Broekmans, K. Hensen, J.-L. Rummens, and P. Stinissen, “Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression,” Journal of Immunology, vol. 180, no. 9, pp. 6411–6420, 2008. View at Google Scholar · View at Scopus
  110. J. Haas, B. Fritzsching, P. Trübswetter et al., “Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines T reg dysfunction in multiple sclerosis,” Journal of Immunology, vol. 179, no. 2, pp. 1322–1330, 2007. View at Google Scholar · View at Scopus
  111. K. Venken, N. Hellings, R. Liblau, and P. Stinissen, “Disturbed regulatory T cell homeostasis in multiple sclerosis,” Trends in Molecular Medicine, vol. 16, no. 2, pp. 58–68, 2010. View at Publisher · View at Google Scholar · View at PubMed
  112. A. L. Zozulya and H. Wiendl, “The role of regulatory T cells in multiple sclerosis,” Nature Clinical Practice Neurology, vol. 4, no. 7, pp. 384–398, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  113. B. M. Segal, “The role of natural killer cells in curbing neuroinflammation,” Journal of Neuroimmunology, vol. 191, no. 1-2, pp. 2–7, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  114. P. L. De Jager, E. Rossin, S. Pyne et al., “Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells,” Brain, vol. 131, no. 7, pp. 1701–1711, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  115. R. C. Axtell, B. A. De Jong, K. Boniface et al., “T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis,” Nature Medicine, vol. 16, no. 4, pp. 406–412, 2010. View at Publisher · View at Google Scholar · View at PubMed
  116. C. T. Weaver and R. D. Hatton, “Interplay between the TH 17 and TReg cell lineages: a (co-)evolutionary perspective,” Nature Reviews Immunology, vol. 9, no. 12, pp. 883–889, 2009. View at Publisher · View at Google Scholar · View at PubMed
  117. A. Ascherio and K. L. Munger, “Epstein-barr virus infection and multiple sclerosis: a review,” Journal of Neuroimmune Pharmacology, vol. 5, no. 3, pp. 271–277, 2010. View at Publisher · View at Google Scholar · View at PubMed
  118. D. J. Pappas and J. R. Oksenberg, “Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy,” Neurology, vol. 74, supplement 1, pp. S62–S69, 2010. View at Publisher · View at Google Scholar · View at PubMed